Pfizer to buy clinical-stage biopharma company, ReViral for $525 million
By, Admin1 min read
Share
Pfizer Inc. and ReViral Ltd. announced that the companies have entered into a definitive agreement under which Pfizer will acquire ReViral, a privately held, clinical-stage biopharmaceutical company.
Found this useful? Share it with your team.
Newsletter
Stay ahead with Clival insights
Subscribe to get the latest updates, data releases and industry information — straight to your inbox.
